Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease - Top-Institutions - MDSpire

Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease

  • By

  • Ning Lyu

  • Michaela Tracy

  • Sebastian Schneeweiss

  • Timothy J. Savage

  • July 10, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Pediatric Gastroenterology

  • #2

    NYU Langone Health
    NYU Langone Health

    New York, NY

    Key Differentiators

    • Pediatric Gastroenterology

  • #3

    Mohammed Bin Rashid University of Medicine and Health Sciences
    Mohammed Bin Rashid University of Medicine and Health Sciences

    Dubai, UAE

    Key Differentiators

    • Pediatric Gastroenterology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Pediatric Gastroenterology

  • #5

    Thomas Jefferson University
    Thomas Jefferson University

    Philadelphia, PA

    Key Differentiators

    • Pediatric Gastroenterology

Original Source(s)

Risk of Infections With Infliximab vs Adalimumab Among Children With Inflammatory Bowel Disease

  • by Ning Lyu, Michaela Tracy, Sebastian Schneeweiss, Timothy J. Savage

  • July 10, 2026

Related Content

Cross-species systems analysis distinguishes inflammatory remodeling from primary mucus secretory failure in inflammatory bowel disease

Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

Empowering healthier lifestyles: patterns of digital tool use, self-efficacy, and affective balance in IBD-patients and a community sample